Havrix

Havrix is a prescription‑only hepatitis A vaccine that contains an inactivated hepatitis A virus adsorbed on aluminium hydroxide, supplied as an injectable solution. The product is manufactured for the European market and is administered intramuscularly to stimulate active immunity against hepatitis A infection. No specific strength is listed on the label, and the formulation is designed for use in adults and children as directed by a healthcare professional.

Havrix is indicated for the prevention of hepatitis A infection in individuals who are at risk of exposure or who seek immunization against the virus.

- Primary prophylaxis for adults and children aged 12 months and older. - Protection for travelers to regions where hepatitis A is endemic. - Immunization of laboratory personnel handling hepatitis A virus. - Use in outbreak settings to control spread of hepatitis A. - Administration as a two‑dose series, with the second dose given 6–12 months after the first.

Following intramuscular injection, Havrix may cause transient reactions; most are mild and resolve without intervention.

Common: - Pain, redness, or swelling at the injection site. - Low‑grade fever. - Headache. - Fatigue or mild malaise. - Nausea.

Serious: - Severe allergic reaction (anaphylaxis) with symptoms such as difficulty breathing, swelling of the face or throat, and rapid heartbeat. - Guillain‑Barré syndrome, a rare neurological disorder characterized by muscle weakness. - Persistent high fever or severe rash. - Severe joint pain. - Seizures.

Healthcare providers should assess individual risk factors and medical history before administering Havrix to ensure safe and effective immunization.

- Defer vaccination in persons with known severe allergy to any vaccine component, including aluminium salts. - Postpone administration in individuals experiencing acute moderate or severe illness. - Use with caution in patients with compromised immune systems; vaccine may be less effective. - Discuss potential risks with pregnant or breastfeeding women, as safety data are limited. - Monitor for signs of anaphylaxis for at least 15 minutes after injection. - Avoid routine revaccination without documented loss of immunity.

Havrix generally has a low potential for drug interactions, but certain medications and vaccines may influence its safety or effectiveness.

Avoid: - Concurrent administration with live‑attenuated vaccines (e.g., measles, mumps, rubella) should be avoided; separate them by at least 4 weeks. - Simultaneous use of immunoglobulin products may reduce the immune response to Havrix.

Use with caution: - Immunosuppressive therapy (e.g., corticosteroids, chemotherapy) may diminish antibody production; consider timing of vaccination. - Antipyretics such as acetaminophen or ibuprofen can be used to manage mild post‑vaccination symptoms, but routine prophylactic use may blunt the immune response. - Blood products or plasma containing hepatitis A antibodies may interfere with vaccine efficacy; schedule vaccination accordingly.